Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas-derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa. In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with a k2/K of 41,400 M-1 s-1 and a koff of 0.00095 s-1. Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant P. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against P. aeruginosa.
CITATION STYLE
Barnes, M. D., Bethel, C. R., Alsop, J., Becka, S. A., Rutter, J. D., Papp-Wallace, K. M., & Bonomoa, R. A. (2018). Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by Relebactam. Antimicrobial Agents and Chemotherapy, 62(5). https://doi.org/10.1128/AAC.02406-17
Mendeley helps you to discover research relevant for your work.